FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
Pre-publication versions of this article are available by contacting firstname.lastname@example.org.
|12 Aug 2015||Submitted||Original manuscript|
|21 Aug 2015||Reviewed||Reviewer Report - Sebastian Krug|
|2 Sep 2015||Reviewed||Reviewer Report - Motoyoshi Tanaka|
|3 Sep 2015||Reviewed||Reviewer Report - Sven Lang|
|6 Oct 2015||Author responded||Author comments - Dannel Yeo|
|Resubmission - Version 2|
|6 Oct 2015||Submitted||Manuscript version 2|
|10 Oct 2015||Reviewed||Reviewer Report - Motoyoshi Tanaka|
|16 Oct 2015||Reviewed||Reviewer Report - Sebastian Krug|
|24 Oct 2015||Reviewed||Reviewer Report - Sven Lang|
|24 Dec 2015||Author responded||Author comments - Dannel Yeo|
|Resubmission - Version 3|
|24 Dec 2015||Submitted||Manuscript version 3|
|8 Jan 2016||Editorially accepted|
|16 Jan 2016||Article published||10.1186/s12885-016-2057-z|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting email@example.com.
You can find further information about the peer review system here.